Literature DB >> 3106053

Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver.

C Caramelo, S Fernández-Gallardo, J C Santos, P Iñarrea, M Sánchez-Crespo, J M López-Novoa, L Hernando.   

Abstract

The levels of platelet-activating factor (paf-acether) were measured in blood and ascitic fluid from cirrhotic patients and in blood from a group of controls, using a recently described technique for extraction and measurement. In addition, activity of acetylhydrolase, the main catabolic enzyme for paf-acether, was also measured. The highest levels of paf-acether in blood were found in decompensated cirrhotics (1.78 +/- 0.62 ng ml-1; mean +/- SD, n = 8). Compensated cirrhotics showed lower blood values (0.79 +/- 0.21, n = 4), but higher than controls (0.20 +/- 0.04, n = 12). Paf-acether levels in ascitic fluid were similar to those of blood. Values of acetylhydrolase in serum were similar in all the groups studied (3.0 +/- 0.4 in cirrhotics vs. 2.3 +/- 0.4 nmol min-1 mg-1 of protein in controls). These data suggest an enhanced production of paf-acether in cirrhotic patients rather than a decreased catabolism. High levels of paf-acether in blood could be involved in the impaired haemodynamics of cirrhotic patients and in their renal function alterations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106053     DOI: 10.1111/j.1365-2362.1987.tb01218.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  19 in total

1.  The hepatopulmonary syndrome: new name, old complexities.

Authors:  R Rodríguez-Roisin; A G Agustí; J Roca
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

2.  Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.

Authors:  Y Yang; E M Nemoto; S A K Harvey; V M Subbotin; C R Gandhi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?

Authors:  R Jalan; E H Forrest; D N Redhead; J F Dillon; P C Hayes
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

4.  Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.

Authors:  Yong-Ping Yang; Xue-Mei Ma; Chun-Ping Wang; Jun Han; Yin-Ying Lu; Yi Xiang; Shu-Hui Su; Yong-Yi Feng
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 5.  Intestinal endotoxins and macrophages as mediators of liver injury.

Authors:  J P Nolan; D S Camara
Journal:  Trans Am Clin Climatol Assoc       Date:  1989

6.  Hepatic and splanchnic nitric oxide activity in patients with cirrhosis.

Authors:  A I Sarela; F M Mihaimeed; J J Batten; B R Davidson; R T Mathie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 7.  Platelet-activating factor in liver injury: a relational scope.

Authors:  Nikolaos-P Karidis; Gregory Kouraklis; Stamatios-E Theocharis
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

8.  Intravascular release of a platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking.

Authors:  T Imaizumi
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

9.  A simple and precise method for the routine determination of platelet-activating factor in blood and urine.

Authors:  C A Demopoulos; N K Andrikopoulos; S Antonopoulou
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

10.  Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.

Authors:  D M Stafforini; M E Carter; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.